Launch related slideshow:
10 Bargains You Can Buy Cheaper
Than The Insiders Did »

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

At PJT Partners, a filing with the SEC revealed that on Tuesday, CEO Paul J. Taubman purchased 16,500 shares of PJT, for a cost of $36.55 each, for a total investment of $603,050. Bargain hunters are able to bag PJT at a price even lower than Taubman did, with shares changing hands as low as $34.83 in trading on Thursday which is 4.7% below Taubman's purchase price. PJT Partners is trading up about 1.5% on the day Thursday. Before this latest buy, Taubman bought PJT at 6 other times during the past year, for a total cost of $2.63M at an average of $26.49 per share.

And at Eagle Pharmaceuticals (EGRX), there was insider buying on Wednesday, by Director Richard A. Edlin who bought 6,000 shares at a cost of $79.44 each, for a trade totaling $476,640. This purchase marks the first one filed by Edlin in the past year. Eagle Pharmaceuticals is trading up about 3.2% on the day Thursday. So far Edlin is in the green, up about 4.6% on their buy based on today's trading high of $83.07.

For MarketNewsVideo.com, I'm Sayoko Murase.